Gilead Sciences to Withdraw Accelerated Approval of Trodelvy in Urothelial Carcinoma
Gilead Sciences Inc., (NASDAQ: GILD), a leading US-based biopharmaceutical company, has announced its intention to...
Jiangsu Hengrui Pharmaceuticals Initiates Phase III Clinical Trial for SHR-A1904 in Gastric Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
MicroPort Sorim CRM’s PLATINIUM Series ICD Receives NMPA Approval, A First for China
MicroPort Sorim CRM, a Chinese medical device company, has announced that it has received market...
Jacobio Pharma’s G12C Inhibitor Gecirasib Earns Orphan Drug Designation in Europe for Pancreatic Cancer
Jacobio Pharma (HKG: 1167), a China-based biopharmaceutical company, has announced that it has received Orphan...
MicroPort NeuroTech’s NUMEN Silk Receives FDA Approval for Embolization Treatment
MicroPort NeuroTech Limited (HKG: 2172), a Chinese medical device company, has announced that it has...
Astellas Pharma’s Vyloy Receives FDA Approval for CLDN18.2 Positive Gastric Cancer Treatment
Astellas Pharma (TYO: 4503) has announced that the U.S. Food and Drug Administration (FDA) has...
Westgene Biopharma’s Pioneering mRNA Vaccine for EBV-Related Tumors Clears IND Hurdle in China
Westgene Biopharma has received approval from the Center for Drug Evaluation (CDE) under the National...
Kanghong Pharmaceutical’s NASH Drug KH629 Receives Clinical Trial Implicit Approval in China
On October 18th, the official website of the Center for Drug Evaluation (CDE) of the...
Beijing Biostar Pharmaceuticals Set to Go Public on HKEX with Focus on Oncology Innovation
On October 18, 2024, the Hong Kong Stock Exchange announced that Beijing Biostar Pharmaceuticals Co.,...
Akeso Biopharma Launches Phase Ib/II Trial for Cadonilimab and AK112 in Pancreatic Cancer
On October 17, ClinicalTrials.gov reported that Akeso Biopharma (HKG: 9926) has initiated a Phase Ib/II...
FDA Extends Review of Amgen’s Lumakras for KRAS G12C mCRC Treatment to January 2025
On October 18, FirstWord reported that the U.S. FDA has extended the review period for...
Shenzhen Chipscreen Advances CS231295 for Cancer Treatment as IND Accepted by NMPA
On October 17, Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that its innovative Class...
Pfizer Partners with TRIANA Biomedicines to Develop Molecular Glue Degraders for Oncology and Other Diseases
Pfizer (NSE: PFIZER), a leading US pharmaceutical company, has entered into a strategic partnership and...
AstraZeneca Files for Market Approval of Tremelimumab in China for Hepatocellular Carcinoma
The Center for Drug Evaluation (CDE) has indicated on its website that AstraZeneca (NASDAQ: AZN),...
MicroPort CardioFlow’s Heart Valve Balloon Dilatation Catheter Alwide Plus Gains Mexican Approval
MicroPort Scientific Corp., a leading Chinese medical device company (HKG: 0853), through its spin-off MicroPort...
Changshan Biochemical Pharmaceutical Wins Marketing Approval for Enoxaparin in Niger
Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced...
Huahai Pharmaceutical Gets FDA Nod for Generic Empagliflozin and Metformin ANDA
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a prominent Chinese pharmaceutical company, has announced the...
Laekna Advances Obesity Treatment Candidate LAE102 with Subcutaneous Dosing in Phase I Study
Laekna, a Sino-US biotech firm, has announced the commencement of a subcutaneous dosing cohort within...
Sanofi Invests EUR 300 Million in Joint Venture with Orano Med for Next-Generation Radioligand Therapies
Sanofi (EPA: SAN), a leading French pharmaceutical company, has entered into a strategic agreement with...
Antengene’s Xpovio Secures Expanded Access in South Korea for Multiple Myeloma Treatment
Antengene Corp., Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that it has received...